Q3 Trading Update
Q3 revenue grew 20% quarter-on-quarter with over 1,000 billable tests processed in the quarter.
vs expectations: in line
- Q3 revenue growth 20% quarter-on-quarter
- Billable tests processed over 1,000 in Q3
Select text to share a quote on X · sign in to keep highlights & notes in your RENX notes
LONDON and NEW YORK, 10 April 2025 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine company with lead testing service kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in chronic kidney disease, announces that Q3 trading has been in-line with expectations delivering 20% quarter-on-quarter revenue growth.
The Company has also reached the key milestone of processing over 1,000 billable tests within the quarter for the first time. The onboarding of a large New York-based primary care network in September 2024 and increasing performance with direct to physician sales efforts have supported the continued growth in testing revenues.
James McCullough, CEO of Renalytix, commented: "Billable testing volume paid by insurance companies, including Medicare, continues to grow and I am very pleased we have crossed the 1,000 billable testing mark. We remain on track to meet our full year expectations and expect to expand distribution of kidneyintelX.dkd with initiatives from both new insurance payors, care networks and hospital systems this year."
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.